Title(s):
Professor of Oncology
Professor of Urology
Professor of Urology
AEGON Professor of Prostate Cancer Research
Co-Director, Prostate Cancer/GU Oncology Program
Co-Director, Chemical Therapeutics
Co-Director, Prostate Cancer/GU Oncology Program
Co-Director, Chemical Therapeutics
Appointment Phone:
410-955-8964
Primary Location:
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Expertise:
Bladder Cancer, Clinical Trials, General Internal Medicine, Kidney Cancer, Medical Oncology, Pain and Palliative Care - Oncology, Prostate Cancer, Testicular Cancer, Urological Oncology, Urology
Education and Experience
Training
- Wayne State University School of Medicine (Detroit MI)/ (1988)
Fellowships
- The Johns Hopkins Hospital (Baltimore MD)/ Sr Clinical Fellow / Oncology (1995)
- The Johns Hopkins Hospital (Baltimore MD)/ Clinical Fellow / Oncology (1992)
Certifications
- Medical Oncology, American Board of Internal Medicine (1995)
- Internal Medicine, American Board of Internal Medicine (1991)
Locations
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
401 N. Broadway
Baltimore, MD 21231
Phone: 410-614-3977
Appointment Phone: 410-955-8964
Location Map
Department / Division
- Oncology
Centers/Institutes
Centers / Institutes
- Brady Urological Institute
- Sidney Kimmel Comprehensive Cancer Center
Bio
Biography
Michael A. Carducci, MD, is a Professor of Oncology and Urology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He is Co-Leader of the Prostate Cancer / GU Oncology Program and the Chemical Therapeutics Program. A translational researcher, Dr. Carducci directs a laboratory program focused on the re-expression of epigenetically silenced genes in cancer cells via the use of small molecules, and manages a portfolio of clinical trials targeted at introducing these small molecules into cancer treatment. Overall, his laboratory and clinical research focus is on the development and evaluation of new therapies for urologic cancers.
A Fellow of the American College of Physicians, Dr. Carducci is a member of several professional organizations, including AACR, ASCO and AUA. Dr. Carducci serves as PI of an NCI phase I clinical trial grant, of a major project in the JH Prostate Cancer SPORE, and leads the Johns Hopkins site for the DOD Prostate Cancer Clinical Trials Consortium grant.
He is the Chair of the Prostate Cancer Subcommittee of ECOG. Dr. Carducci is a full member of the Investigational Drug Steering Committee for the NCI.
A Fellow of the American College of Physicians, Dr. Carducci is a member of several professional organizations, including AACR, ASCO and AUA. Dr. Carducci serves as PI of an NCI phase I clinical trial grant, of a major project in the JH Prostate Cancer SPORE, and leads the Johns Hopkins site for the DOD Prostate Cancer Clinical Trials Consortium grant.
He is the Chair of the Prostate Cancer Subcommittee of ECOG. Dr. Carducci is a full member of the Investigational Drug Steering Committee for the NCI.
Physician Title
AEGON Professor of Prostate Cancer Research
Co-Director, Prostate Cancer/GU Oncology Program
Co-Director, Chemical Therapeutics
Co-Director, Prostate Cancer/GU Oncology Program
Co-Director, Chemical Therapeutics
Awards and Honors
2011 Michaele Christian Oncology Development Award. The award was given to Carducci to honor his contribution to the development of novel agents for cancer therapy.
Journal citations continued:
Keizman, D.; Zahurak, M.; Sinibaldi, V.; Carducci, M.; Denmeade, S.; Drake, C.; Pili, R.; Antonarakis, E.S.; Hudock, S.; Eisenberger, M. Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study. Clin Cancer Res. 2010 Nov 1;16(21):5269-5276.
Messersmith, W.A.; Jimeno, A.; Jacene, H.; Zhao, M.; Kulesza, P.; Laheru, D.A.; Kahn, Y.; Spira, A.; Dancey, J.; Iacobuzio-Donahue, C.; Donehower, R.C.; Carducci, M.; Rudek, M.A.; Hidalgo, M. Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer. Clin Colorectal Cancer. 2010 Dec;9(5):297-304.
Pratz, K.W.; Cho, E.; Levis, M.J.; Karp, J.E.; Gore, S.D.; McDevitt, M.; Stine, A.; Zhao, M.; Baker, S.D.; Carducci, M.A.; Wright, J.J.; Rudek, M.A.; Smith, B.D. A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias. Leukemia. 2010 Aug;24(8):1437-1444.
Rathkopf, D.; Liu, G.; Carducci, M.A.; Eisenberger, M.A.; Anand, A.; Morris, M.; Slovin, S.F.; Sasaki, Y.; Takahashi, S.; Ozono, S.; Fung, N.K.; Cheng, S.; Gan, J.; Gottardis, M.M.; Obermeier, M.; Reddy, J.; Zhang, S.; Vakkalagadda, B.J.; Wilding, G.; Scher, H.I. Phase I Dose-Escalation Study of the Novel Anti-androgen BMS-641988 in Patients with Castration-Resistant Prostate Cancer. Clin Cancer Res. 2010 Dec 3.
Resta, L.P.; Pili, R.; Eisenberger, M.A.; Spitz, A.; King, S.; Porter, J.; Franke, A.; Boinpally, R.; Carducci, M.A.; Sweeney, C.J. A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone. Cancer Chemother Pharmacol. 2010 May 6.
Journal citations continued:
Keizman, D.; Zahurak, M.; Sinibaldi, V.; Carducci, M.; Denmeade, S.; Drake, C.; Pili, R.; Antonarakis, E.S.; Hudock, S.; Eisenberger, M. Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study. Clin Cancer Res. 2010 Nov 1;16(21):5269-5276.
Messersmith, W.A.; Jimeno, A.; Jacene, H.; Zhao, M.; Kulesza, P.; Laheru, D.A.; Kahn, Y.; Spira, A.; Dancey, J.; Iacobuzio-Donahue, C.; Donehower, R.C.; Carducci, M.; Rudek, M.A.; Hidalgo, M. Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer. Clin Colorectal Cancer. 2010 Dec;9(5):297-304.
Pratz, K.W.; Cho, E.; Levis, M.J.; Karp, J.E.; Gore, S.D.; McDevitt, M.; Stine, A.; Zhao, M.; Baker, S.D.; Carducci, M.A.; Wright, J.J.; Rudek, M.A.; Smith, B.D. A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias. Leukemia. 2010 Aug;24(8):1437-1444.
Rathkopf, D.; Liu, G.; Carducci, M.A.; Eisenberger, M.A.; Anand, A.; Morris, M.; Slovin, S.F.; Sasaki, Y.; Takahashi, S.; Ozono, S.; Fung, N.K.; Cheng, S.; Gan, J.; Gottardis, M.M.; Obermeier, M.; Reddy, J.; Zhang, S.; Vakkalagadda, B.J.; Wilding, G.; Scher, H.I. Phase I Dose-Escalation Study of the Novel Anti-androgen BMS-641988 in Patients with Castration-Resistant Prostate Cancer. Clin Cancer Res. 2010 Dec 3.
Resta, L.P.; Pili, R.; Eisenberger, M.A.; Spitz, A.; King, S.; Porter, J.; Franke, A.; Boinpally, R.; Carducci, M.A.; Sweeney, C.J. A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone. Cancer Chemother Pharmacol. 2010 May 6.
Expertise
- Bladder Cancer
- Clinical Trials
- General Internal Medicine
- Kidney Cancer
- Medical Oncology
- Pain and Palliative Care - Oncology
- Prostate Cancer
- Testicular Cancer
- Urological Oncology
- Urology
Research
Research and Publications
Research Summary:
Dr. Carducci's research focus is on the development and evaluation of new therapies for genitourinary cancers, specifically prostate and renal cancers. Areas of particular interest are bone-targeted therapies, epigenetic strategies, as well as general early phase drug development leading to first-in-human clinical trials.
Journal Citations:
Qian, D.Z.; Kachhap, S.K.; Collis, S.J.; Verheul, H.M.; Carducci, M.A.; Atadja, P.; Pili, R. Class II Histone Deacetylases Are Associated with VHL-Independent Regulation of Hypoxia-Inducible Factor 1{alpha}. Cancer Res. 2006 Sep 1;66(17):8814-8821.
Simons, J.W.; Carducci, M.A.; Mikhak, B.; Lim, M.; Biedrzycki, B.; Borellini, F.; Clift, S.M.; Hege, K.M.; Ando, D.G.; Piantadosi, S.; Mulligan, R.; Nelson, W.G. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naive prostate cancer. Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3394-3401.
Sinibaldi, V.J.; Elza-Brown, K.; Schmidt, J.; Eisenberger, M.A.; Rosenbaum, E.; Denmeade, S.R.; Pili, R.; Walczak, J.; Baker, S.D.; Zahurak, M.; Carducci, M.A. Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma. American journal of clinical oncology. 2006 Aug;29(4):395-398.
Small, E.J.; Carducci, M.A.; Burke, J.M.; Rodriguez, R.; Fong, L.; van Ummersen, L.; Yu, D.C.; Aimi, J.; Ando, D.; Working, P.; Kirn, D.; Wilding, G. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther. 2006 Jul;14(1):107-117.
Thompson, I.M.; Carroll, P.R.; Carducci, M.A. Recommendations for defining and treating high risk localized prostate cancer. J Urol. 2006 Dec;176(6 Pt 2):S6-S10; quiz S13-15.
Xia, Q.; Sung, J.; Chowdhury, W.; Chen, C.L.; Hoti, N.; Shabbeer, S.; Carducci, M.; Rodriguez, R. Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. Cancer Res. 2006 Jul 15;66(14):7237-7244.
Armstrong, A.J.; Garrett-Mayer, E.; Ou Yang, Y.C.; Carducci, M.A.; Tannock, I.; de Wit, R.; Eisenberger, M. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol. 2007 Sep 1;25(25):3965-3970.
Bajaj, G.K.; Zhang, Z.; Garrett-Mayer, E.; Drew, R.; Sinibaldi, V.; Pili, R.; Denmeade, S.R.; Carducci, M.A.; Eisenberger, M.A.; DeWeese, T.L. Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy. Urology. 2007 Mar;69(3):526-531.
Basaria, S.; Muller, D.C.; Carducci, M.A.; Egan, J.; Dobs, A.S. Relation between duration of androgen deprivation therapy and degree of insulin resistance in men with prostate cancer. Archives of internal medicine. 2007 Mar 26;167(6):612-613.
Basch, E.M.; Somerfield, M.R.; Beer, T.M.; Carducci, M.A.; Higano, C.S.; Hussain, M.H.; Scher, H.I. American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer. J Clin Oncol. 2007 Nov 20;25(33):5313-5318.
Beer, T.M.; Ryan, C.W.; Venner, P.M.; Petrylak, D.P.; Chatta, G.S.; Ruether, J.D.; Redfern, C.H.; Fehrenbacher, L.; Saleh, M.N.; Waterhouse, D.M.; Carducci, M.A.; Vicario, D.; Dreicer, R.; Higano, C.S.; Ahmann, F.R.; Chi, K.N.; Henner, W.D.; Arroyo, A.; Clow, F.W. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol. 2007 Feb 20;25(6):669-674.
Carducci, M.A.; Saad, F.; Abrahamsson, P.A.; Dearnaley, D.P.; Schulman, C.C.; North, S.A.; Sleep, D.J.; Isaacson, J.D.; Nelson, J.B. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer. 2007 Nov 1;110(9):1959-1966.
Collins, C.; Carducci, M.A.; Eisenberger, M.A.; Isaacs, J.T.; Partin, A.W.; Pili, R.; Sinibaldi, V.J.; Walczak, J.S.; Denmeade, S.R. Preclinical and Clinical Studies With the Multi-Kinase Inhibitor CEP-701 as Treatment for Prostate Cancer Demonstrate the Inadequacy of PSA Response as a Primary Endpoint. Cancer Biol Ther. 2007 Jun 5;6(9).
Heath, E., Carducci, M.A. Targeted Therapy Trials in Prostate Cancer:Signaling Networks, Genetics and New Treatment Strategies. Vol. In press. Totowa, NJ: Humana Press, Inc.; 2007.
Hudes, G.; Carducci, M.; Tomczak, P.; Dutcher, J.; Figlin, R.; Kapoor, A.; Staroslawska, E.; Sosman, J.; McDermott, D.; Bodrogi, I.; Kovacevic, Z.; Lesovoy, V.; Schmidt-Wolf, I.G.; Barbarash, O.; Gokmen, E.; O'Toole, T.; Lustgarten, S.; Moore, L.; Motzer, R.J. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007 May 31;356(22):2271-2281.
Kachhap, S.K.; Faith, D.; Qian, D.Z.; Shabbeer, S.; Galloway, N.L.; Pili, R.; Denmeade, S.R.; DeMarzo, A.M.; Carducci, M.A. The N-Myc down regulated Gene1 (NDRG1) Is a Rab4a effector involved in vesicular recycling of E-cadherin. PLoS ONE. 2007;2(9):e844.
Messersmith, W.A.; Rudek, M.A.; Baker, S.D.; Zhao, M.; Collins, C.; Colevas, A.D.; Donehower, R.C.; Carducci, M.A.; Wolff, A.C. Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumours. Eur J Cancer. 2007 Jan;43(1):78-86.
Shabbeer, S.; Kortenhorst, M.S.; Kachhap, S.; Galloway, N.; Rodriguez, R.; Carducci, M.A. Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo. Prostate. 2007 Jul 1;67(10):1099-1110.
Verheul, H.M.; Qian, D.Z.; Carducci, M.A.; Pili, R. Sequence-dependent antitumor effects of differentiation agents in combination with cell cycle-dependent cytotoxic drugs. Cancer Chemother Pharmacol. 2007 Aug;60(3):329-339.
Walczak, J.R.; Carducci, M.A. Prostate cancer: a practical approach to current management of recurrent disease. Mayo Clin Proc. 2007 Feb;82(2):243-249.
Zhou, S.; Kachhap, S.; Sun, W.; Wu, G.; Chuang, A.; Poeta, L.; Grumbine, L.; Mithani, S.K.; Chatterjee, A.; Koch, W.; Westra, W.H.; Maitra, A.; Glazer, C.; Carducci, M.; Sidransky, D.; McFate, T.; Verma, A.; Califano, J.A. Frequency and phenotypic implications of mitochondrial DNA mutations in human squamous cell cancers of the head and neck. Proc Natl Acad Sci U S A. 2007 May 1;104(18):7540-7545.
Alumkal, J.J.; Zhang, Z.; Humphreys, E.B.; Bennett, C.; Mangold, L.A.; Carducci, M.A.; Partin, A.W.; Garrett-Mayer, E.; DeMarzo, A.M.; Herman, J.G. Effect of DNA methylation on identification of aggressive prostate cancer. Urology. 2008 Dec;72(6):1234-1239.
Baselga, J.; Rothenberg, M.L.; Tabernero, J.; Seoane, J.; Daly, T.; Cleverly, A.; Berry, B.; Rhoades, S.K.; Ray, C.A.; Fill, J.; Farrington, D.L.; Wallace, L.A.; Yingling, J.M.; Lahn, M.; Arteaga, C.; Carducci, M. TGF-beta signalling-related markers in cancer patients with bone metastasis. Biomarkers. 2008 Mar;13(2):217-236.
Bonfils, C.; Kalita, A.; Dubay, M.; Siu, L.L.; Carducci, M.A.; Reid, G.; Martell, R.E.; Besterman, J.M.; Li, Z. Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay. Clin Cancer Res. 2008 Jun 1;14(11):3441-3449.
Heath, E.I.; Hillman, D.W.; Vaishampayan, U.; Sheng, S.; Sarkar, F.; Harper, F.; Gaskins, M.; Pitot, H.C.; Tan, W.; Ivy, S.P.; Pili, R.; Carducci, M.A.; Erlichman, C.; Liu, G. A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Cancer Res. 2008 Dec 1;14(23):7940-7946.
Hooker, A.C.; Ten Tije, A.J.; Carducci, M.A.; Weber, J.; Garrett-Mayer, E.; Gelderblom, H.; McGuire, W.P.; Verweij, J.; Karlsson, M.O.; Baker, S.D. Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P4503A activity measurements. Clin Pharmacol Ther. 2008 Jul;84(1):111-118.
Jimeno, A.; Rudek, M.A.; Purcell, T.; Laheru, D.A.; Messersmith, W.A.; Dancey, J.; Carducci, M.A.; Baker, S.D.; Hidalgo, M.; Donehower, R.C. Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors. Cancer Chemother Pharmacol. 2008 Mar;61(3):423-433.
Kass, N.; Taylor, H.; Fogarty, L.; Sugarman, J.; Goodman, S.N.; Goodwin-Landher, A.; Carducci, M.; Hurwitz, H. Purpose and benefits of early phase cancer trials: what do oncologists say? What do patients hear? J Empir Res Hum Res Ethics. 2008 Sep;3(3):57-68.
Kortenhorst, M.S.; Zahurak, M.; Shabbeer, S.; Kachhap, S.; Galloway, N.; Parmigiani, G.; Verheul, H.M.; Carducci, M.A. A multiple-loop, double-cube microarray design applied to prostate cancer cell lines with variable sensitivity to histone deacetylase inhibitors. Clin Cancer Res. 2008 Nov 1;14(21):6886-6894.
Lassiter, L.K.; Tummala, M.K.; Hussain, M.H.; Stadler, W.M.; Petrylak, D.P.; Carducci, M.A. Phase II open-label study of oral piritrexim in patients with advanced carcinoma of the urothelium who have experienced failure with standard chemotherapy. Clin Genitourin Cancer. 2008 Mar;6(1):31-35.
Makarov, D.V.; Humphreys, E.B.; Mangold, L.A.; Carducci, M.A.; Partin, A.W.; Eisenberger, M.A.; Walsh, P.C.; Trock, B.J. The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy. J Urol. 2008 Jan;179(1):156-161; discussion 161-152.
Nelson, J.B.; Love, W.; Chin, J.L.; Saad, F.; Schulman, C.C.; Sleep, D.J.; Qian, J.; Steinberg, J.; Carducci, M. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer. 2008 Nov 1;113(9):2478-2487.
Pili, R., J. Walczak, M. A. Carducci, and S. R. Denmeade. Genitourinary Cancer. In: Donhower, D.E.a.R., editor, Current Cancer in Therapeutics. Philadelphia: Current Medicine Group; 2008.
Rathkopf, D.; Carducci, M.A.; Morris, M.J.; Slovin, S.F.; Eisenberger, M.A.; Pili, R.; Denmeade, S.R.; Kelsen, M.; Curley, T.; Halter, M.; Collins, C.; Fleisher, M.; Heller, G.; Baker, S.D.; Scher, H.I. Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer. J Clin Oncol. 2008 Jun 20;26(18):2959-2965.
Rudin, C.M.; Liu, W.; Desai, A.; Karrison, T.; Jiang, X.; Janisch, L.; Das, S.; Ramirez, J.; Poonkuzhali, B.; Schuetz, E.; Fackenthal, D.L.; Chen, P.; Armstrong, D.K.; Brahmer, J.R.; Fleming, G.F.; Vokes, E.E.; Carducci, M.A.; Ratain, M.J. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol. 2008 Mar 1;26(7):1119-1127.
Scher, H.I.; Halabi, S.; Tannock, I.; Morris, M.; Sternberg, C.N.; Carducci, M.A.; Eisenberger, M.A.; Higano, C.; Bubley, G.J.; Dreicer, R.; Petrylak, D.; Kantoff, P.; Basch, E.; Kelly, W.K.; Figg, W.D.; Small, E.J.; Beer, T.M.; Wilding, G.; Martin, A.; Hussain, M. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008 Mar 1;26(7):1148-1159.
Siu, L.L.; Pili, R.; Duran, I.; Messersmith, W.A.; Chen, E.X.; Sullivan, R.; MacLean, M.; King, S.; Brown, S.; Reid, G.K.; Li, Z.; Kalita, A.M.; Laille, E.J.; Besterman, J.M.; Martell, R.E.; Carducci, M.A. Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. J Clin Oncol. 2008 Apr 20;26(12):1940-1947.
Snyder, C.F.; Garrett-Mayer, E.; Brahmer, J.R.; Carducci, M.A.; Pili, R.; Stearns, V.; Wolff, A.C.; Dy, S.M.; Wu, A.W. Symptoms, supportive care needs, and function in cancer patients: how are they related? Qual Life Res. 2008 Jun;17(5):665-677.
Antonarakis, E.S.; Heath, E.I.; Walczak, J.R.; Nelson, W.G.; Fedor, H.; De Marzo, A.M.; Zahurak, M.L.; Piantadosi, S.; Dannenberg, A.J.; Gurganus, R.T.; Baker, S.D.; Parnes, H.L.; DeWeese, T.L.; Partin, A.W.; Carducci, M.A. Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J Clin Oncol. 2009 Oct 20;27(30):4986-4993.
Baker, S.D.; Verweij, J.; Cusatis, G.A.; van Schaik, R.H.; Marsh, S.; Orwick, S.J.; Franke, R.M.; Hu, S.; Schuetz, E.G.; Lamba, V.; Messersmith, W.A.; Wolff, A.C.; Carducci, M.A.; Sparreboom, A. Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther. 2009 Feb;85(2):155-163.
Diaz, L.A., Jr.; Messersmith, W.; Sokoll, L.; Sinibaldi, V.; Moore, S.; Carducci, M.; Eisenberger, M. TNF-blockade in patients with advanced hormone refractory prostate cancer. Invest New Drugs. 2009 Oct 21.
Kass, N.E.; Sugarman, J.; Medley, A.M.; Fogarty, L.A.; Taylor, H.A.; Daugherty, C.K.; Emerson, M.R.; Goodman, S.N.; Hlubocky, F.J.; Hurwitz, H.I.; Carducci, M.; Goodwin-Landher, A. An intervention to improve cancer patients' understanding of early-phase clinical trials. Irb. 2009 May-Jun;31(3):1-10.
Keizman, D.; Carducci, M.A. Intermittent androgen deprivation-questions remain. Nat Rev Urol. 2009 Aug;6(8):412-414.
Kortenhorst, M.S.; Isharwal, S.; van Diest, P.J.; Chowdhury, W.H.; Marlow, C.; Carducci, M.A.; Rodriguez, R.; Veltri, R.W. Valproic acid causes dose- and time-dependent changes in nuclear structure in prostate cancer cells in vitro and in vivo. Mol Cancer Ther. 2009 Apr;8(4):802-808.
Lin, J.; Carducci, M.A. HIF-1alpha inhibition as a novel mechanism of cardiac glycosides in cancer therapeutics. Expert Opin Investig Drugs. 2009 Feb;18(2):241-243.
Lin, J.; Denmeade, S.; Carducci, M.A. HIF-1alpha and calcium signaling as targets for treatment of prostate cancer by cardiac glycosides. Current cancer drug targets. 2009 Nov;9(7):881-887.
Lin, J.; Gilbert, J.; Rudek, M.A.; Zwiebel, J.A.; Gore, S.; Jiemjit, A.; Zhao, M.; Baker, S.D.; Ambinder, R.F.; Herman, J.G.; Donehower, R.C.; Carducci, M.A. A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors. Clin Cancer Res. 2009 Oct 1;15(19):6241-6249.
Lin, J.; Sinibaldi, V.J.; Carducci, M.A.; Denmeade, S.; Song, D.; Deweese, T.; Eisenberger, M.A. Phase I trial with a combination of docetaxel and (153)Sm-lexidronam in patients with castration-resistant metastatic prostate cancer. Urol Oncol. 2009 Dec 3.
Liu, W.; Laitinen, S.; Khan, S.; Vihinen, M.; Kowalski, J.; Yu, G.; Chen, L.; Ewing, C.M.; Eisenberger, M.A.; Carducci, M.A.; Nelson, W.G.; Yegnasubramanian, S.; Luo, J.; Wang, Y.; Xu, J.; Isaacs, W.B.; Visakorpi, T.; Bova, G.S. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med. 2009 May;15(5):559-565.
Morris, M.J.; Basch, E.M.; Wilding, G.; Hussain, M.; Carducci, M.A.; Higano, C.; Kantoff, P.; Oh, W.K.; Small, E.J.; George, D.; Mathew, P.; Beer, T.M.; Slovin, S.F.; Ryan, C.; Logothetis, C.; Scher, H.I. Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research. Clin Genitourin Cancer. 2009 Jan;7(1):51-57.
Motzer, R.J.; Agarwal, N.; Beard, C.; Bolger, G.B.; Boston, B.; Carducci, M.A.; Choueiri, T.K.; Figlin, R.A.; Fishman, M.; Hancock, S.L.; Hudes, G.R.; Jonasch, E.; Kessinger, A.; Kuzel, T.M.; Lange, P.H.; Levine, E.G.; Margolin, K.A.; Michaelson, M.D.; Olencki, T.; Pili, R.; Redman, B.G.; Robertson, C.N.; Schwartz, L.H.; Sheinfeld, J.; Wang, J. NCCN clinical practice guidelines in oncology: testicular cancer. J Natl Compr Canc Netw. 2009 Jun;7(6):672-693.
Motzer, R.J.; Agarwal, N.; Beard, C.; Bolger, G.B.; Boston, B.; Carducci, M.A.; Choueiri, T.K.; Figlin, R.A.; Fishman, M.; Hancock, S.L.; Hudes, G.R.; Jonasch, E.; Kessinger, A.; Kuzel, T.M.; Lange, P.H.; Levine, E.G.; Margolin, K.A.; Michaelson, M.D.; Olencki, T.; Pili, R.; Redman, B.G.; Robertson, C.N.; Schwartz, L.H.; Sheinfeld, J.; Wang, J. NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw. 2009 Jun;7(6):618-630.
Shabbeer, S.; Sobolewski, M.; Anchoori, R.K.; Kachhap, S.; Davidson, N.; Carducci, M.A.; Khan, S.R. Fenugreek: A naturally occurring edible spice as an anticancer agent. Cancer Biol Ther. 2009 Feb 18;8(3).
Shariat, S.F.; Karam, J.A.; Karakiewicz, P.I. Words of wisdom. Re: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ; Global ARCC Trial. N Engl J Med 2007;356:2271-81. Eur Urol. 2009 Jan;55(1):250-252.
Sharma, P.; Wisniewski, A.; Braga-Basaria, M.; Xu, X.; Yep, M.; Denmeade, S.; Dobs, A.S.; DeWeese, T.; Carducci, M.; Basaria, S. Lack of an effect of high dose isoflavones in men with prostate cancer undergoing androgen deprivation therapy. J Urol. 2009 Nov;182(5):2265-2272.
Snyder, C.F.; Garrett-Mayer, E.; Blackford, A.L.; Brahmer, J.R.; Carducci, M.A.; Pili, R.; Stearns, V.; Wolff, A.C.; Dy, S.M.; Wu, A.W. Concordance of cancer patients' function, symptoms, and supportive care needs. Qual Life Res. 2009 Oct;18(8):991-998.
Antonarakis, E.S.; Carducci, M.A. Future directions in castrate-resistant prostate cancer therapy. Clin Genitourin Cancer. 2010 Dec 1;8(1):37-46.
Antonarakis, E.S.; Carducci, M.A. Combining low-dose cyclophosphamide with GM-CSF-secreting prostate cancer immunotherapy enhances antitumor immune effects. Expert Opin Investig Drugs. 2010 Feb;19(2):311-314.
Antonarakis, E.S.; Carducci, M.A.; Eisenberger, M.A. Novel targeted therapeutics for metastatic castration-resistant prostate cancer. Cancer Lett. 2010 May 1;291(1):1-13.
Armstrong, A.J.; Netto, G.J.; Rudek, M.A.; Halabi, S.; Wood, D.P.; Creel, P.A.; Mundy, K.; Davis, S.L.; Wang, T.; Albadine, R.; Schultz, L.; Partin, A.W.; Jimeno, A.; Fedor, H.; Febbo, P.G.; George, D.J.; Gurganus, R.; De Marzo, A.M.; Carducci, M.A. A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer. Clin Cancer Res. 2010 Jun 1;16(11):3057-3066.
Cetin, K.; Beebe-Dimmer, J.L.; Fryzek, J.P.; Markus, R.; Carducci, M.A. Recent time trends in the epidemiology of stage IV prostate cancer in the United States: analysis of data from the Surveillance, Epidemiology, and End Results Program. Urology. 2010 Jun;75(6):1396-1404.
DiPaola, R.S.; Chen, Y.H.; Stein, M.; Vaughn, D.; Patrick-Miller, L.; Carducci, M.; Roth, B.; White, E.; Wilding, G. A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899. J Transl Med. 2010;8:20.
Franke, R.M.; Carducci, M.A.; Rudek, M.A.; Baker, S.D.; Sparreboom, A. Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. J Clin Oncol. 2010 Oct 20;28(30):4562-4567.
Kachhap, S.K.; Rosmus, N.; Collis, S.J.; Kortenhorst, M.S.; Wissing, M.D.; Hedayati, M.; Shabbeer, S.; Mendonca, J.; Deangelis, J.; Marchionni, L.; Lin, J.; Hoti, N.; Nortier, J.W.; DeWeese, T.L.; Hammers, H.; Carducci, M.A. Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor. PLoS One. 2010;5(6):e11208.
Dr. Carducci's research focus is on the development and evaluation of new therapies for genitourinary cancers, specifically prostate and renal cancers. Areas of particular interest are bone-targeted therapies, epigenetic strategies, as well as general early phase drug development leading to first-in-human clinical trials.
Journal Citations:
Qian, D.Z.; Kachhap, S.K.; Collis, S.J.; Verheul, H.M.; Carducci, M.A.; Atadja, P.; Pili, R. Class II Histone Deacetylases Are Associated with VHL-Independent Regulation of Hypoxia-Inducible Factor 1{alpha}. Cancer Res. 2006 Sep 1;66(17):8814-8821.
Simons, J.W.; Carducci, M.A.; Mikhak, B.; Lim, M.; Biedrzycki, B.; Borellini, F.; Clift, S.M.; Hege, K.M.; Ando, D.G.; Piantadosi, S.; Mulligan, R.; Nelson, W.G. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naive prostate cancer. Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3394-3401.
Sinibaldi, V.J.; Elza-Brown, K.; Schmidt, J.; Eisenberger, M.A.; Rosenbaum, E.; Denmeade, S.R.; Pili, R.; Walczak, J.; Baker, S.D.; Zahurak, M.; Carducci, M.A. Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma. American journal of clinical oncology. 2006 Aug;29(4):395-398.
Small, E.J.; Carducci, M.A.; Burke, J.M.; Rodriguez, R.; Fong, L.; van Ummersen, L.; Yu, D.C.; Aimi, J.; Ando, D.; Working, P.; Kirn, D.; Wilding, G. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther. 2006 Jul;14(1):107-117.
Thompson, I.M.; Carroll, P.R.; Carducci, M.A. Recommendations for defining and treating high risk localized prostate cancer. J Urol. 2006 Dec;176(6 Pt 2):S6-S10; quiz S13-15.
Xia, Q.; Sung, J.; Chowdhury, W.; Chen, C.L.; Hoti, N.; Shabbeer, S.; Carducci, M.; Rodriguez, R. Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. Cancer Res. 2006 Jul 15;66(14):7237-7244.
Armstrong, A.J.; Garrett-Mayer, E.; Ou Yang, Y.C.; Carducci, M.A.; Tannock, I.; de Wit, R.; Eisenberger, M. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol. 2007 Sep 1;25(25):3965-3970.
Bajaj, G.K.; Zhang, Z.; Garrett-Mayer, E.; Drew, R.; Sinibaldi, V.; Pili, R.; Denmeade, S.R.; Carducci, M.A.; Eisenberger, M.A.; DeWeese, T.L. Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy. Urology. 2007 Mar;69(3):526-531.
Basaria, S.; Muller, D.C.; Carducci, M.A.; Egan, J.; Dobs, A.S. Relation between duration of androgen deprivation therapy and degree of insulin resistance in men with prostate cancer. Archives of internal medicine. 2007 Mar 26;167(6):612-613.
Basch, E.M.; Somerfield, M.R.; Beer, T.M.; Carducci, M.A.; Higano, C.S.; Hussain, M.H.; Scher, H.I. American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer. J Clin Oncol. 2007 Nov 20;25(33):5313-5318.
Beer, T.M.; Ryan, C.W.; Venner, P.M.; Petrylak, D.P.; Chatta, G.S.; Ruether, J.D.; Redfern, C.H.; Fehrenbacher, L.; Saleh, M.N.; Waterhouse, D.M.; Carducci, M.A.; Vicario, D.; Dreicer, R.; Higano, C.S.; Ahmann, F.R.; Chi, K.N.; Henner, W.D.; Arroyo, A.; Clow, F.W. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol. 2007 Feb 20;25(6):669-674.
Carducci, M.A.; Saad, F.; Abrahamsson, P.A.; Dearnaley, D.P.; Schulman, C.C.; North, S.A.; Sleep, D.J.; Isaacson, J.D.; Nelson, J.B. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer. 2007 Nov 1;110(9):1959-1966.
Collins, C.; Carducci, M.A.; Eisenberger, M.A.; Isaacs, J.T.; Partin, A.W.; Pili, R.; Sinibaldi, V.J.; Walczak, J.S.; Denmeade, S.R. Preclinical and Clinical Studies With the Multi-Kinase Inhibitor CEP-701 as Treatment for Prostate Cancer Demonstrate the Inadequacy of PSA Response as a Primary Endpoint. Cancer Biol Ther. 2007 Jun 5;6(9).
Heath, E., Carducci, M.A. Targeted Therapy Trials in Prostate Cancer:Signaling Networks, Genetics and New Treatment Strategies. Vol. In press. Totowa, NJ: Humana Press, Inc.; 2007.
Hudes, G.; Carducci, M.; Tomczak, P.; Dutcher, J.; Figlin, R.; Kapoor, A.; Staroslawska, E.; Sosman, J.; McDermott, D.; Bodrogi, I.; Kovacevic, Z.; Lesovoy, V.; Schmidt-Wolf, I.G.; Barbarash, O.; Gokmen, E.; O'Toole, T.; Lustgarten, S.; Moore, L.; Motzer, R.J. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007 May 31;356(22):2271-2281.
Kachhap, S.K.; Faith, D.; Qian, D.Z.; Shabbeer, S.; Galloway, N.L.; Pili, R.; Denmeade, S.R.; DeMarzo, A.M.; Carducci, M.A. The N-Myc down regulated Gene1 (NDRG1) Is a Rab4a effector involved in vesicular recycling of E-cadherin. PLoS ONE. 2007;2(9):e844.
Messersmith, W.A.; Rudek, M.A.; Baker, S.D.; Zhao, M.; Collins, C.; Colevas, A.D.; Donehower, R.C.; Carducci, M.A.; Wolff, A.C. Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumours. Eur J Cancer. 2007 Jan;43(1):78-86.
Shabbeer, S.; Kortenhorst, M.S.; Kachhap, S.; Galloway, N.; Rodriguez, R.; Carducci, M.A. Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo. Prostate. 2007 Jul 1;67(10):1099-1110.
Verheul, H.M.; Qian, D.Z.; Carducci, M.A.; Pili, R. Sequence-dependent antitumor effects of differentiation agents in combination with cell cycle-dependent cytotoxic drugs. Cancer Chemother Pharmacol. 2007 Aug;60(3):329-339.
Walczak, J.R.; Carducci, M.A. Prostate cancer: a practical approach to current management of recurrent disease. Mayo Clin Proc. 2007 Feb;82(2):243-249.
Zhou, S.; Kachhap, S.; Sun, W.; Wu, G.; Chuang, A.; Poeta, L.; Grumbine, L.; Mithani, S.K.; Chatterjee, A.; Koch, W.; Westra, W.H.; Maitra, A.; Glazer, C.; Carducci, M.; Sidransky, D.; McFate, T.; Verma, A.; Califano, J.A. Frequency and phenotypic implications of mitochondrial DNA mutations in human squamous cell cancers of the head and neck. Proc Natl Acad Sci U S A. 2007 May 1;104(18):7540-7545.
Alumkal, J.J.; Zhang, Z.; Humphreys, E.B.; Bennett, C.; Mangold, L.A.; Carducci, M.A.; Partin, A.W.; Garrett-Mayer, E.; DeMarzo, A.M.; Herman, J.G. Effect of DNA methylation on identification of aggressive prostate cancer. Urology. 2008 Dec;72(6):1234-1239.
Baselga, J.; Rothenberg, M.L.; Tabernero, J.; Seoane, J.; Daly, T.; Cleverly, A.; Berry, B.; Rhoades, S.K.; Ray, C.A.; Fill, J.; Farrington, D.L.; Wallace, L.A.; Yingling, J.M.; Lahn, M.; Arteaga, C.; Carducci, M. TGF-beta signalling-related markers in cancer patients with bone metastasis. Biomarkers. 2008 Mar;13(2):217-236.
Bonfils, C.; Kalita, A.; Dubay, M.; Siu, L.L.; Carducci, M.A.; Reid, G.; Martell, R.E.; Besterman, J.M.; Li, Z. Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay. Clin Cancer Res. 2008 Jun 1;14(11):3441-3449.
Heath, E.I.; Hillman, D.W.; Vaishampayan, U.; Sheng, S.; Sarkar, F.; Harper, F.; Gaskins, M.; Pitot, H.C.; Tan, W.; Ivy, S.P.; Pili, R.; Carducci, M.A.; Erlichman, C.; Liu, G. A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Cancer Res. 2008 Dec 1;14(23):7940-7946.
Hooker, A.C.; Ten Tije, A.J.; Carducci, M.A.; Weber, J.; Garrett-Mayer, E.; Gelderblom, H.; McGuire, W.P.; Verweij, J.; Karlsson, M.O.; Baker, S.D. Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P4503A activity measurements. Clin Pharmacol Ther. 2008 Jul;84(1):111-118.
Jimeno, A.; Rudek, M.A.; Purcell, T.; Laheru, D.A.; Messersmith, W.A.; Dancey, J.; Carducci, M.A.; Baker, S.D.; Hidalgo, M.; Donehower, R.C. Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors. Cancer Chemother Pharmacol. 2008 Mar;61(3):423-433.
Kass, N.; Taylor, H.; Fogarty, L.; Sugarman, J.; Goodman, S.N.; Goodwin-Landher, A.; Carducci, M.; Hurwitz, H. Purpose and benefits of early phase cancer trials: what do oncologists say? What do patients hear? J Empir Res Hum Res Ethics. 2008 Sep;3(3):57-68.
Kortenhorst, M.S.; Zahurak, M.; Shabbeer, S.; Kachhap, S.; Galloway, N.; Parmigiani, G.; Verheul, H.M.; Carducci, M.A. A multiple-loop, double-cube microarray design applied to prostate cancer cell lines with variable sensitivity to histone deacetylase inhibitors. Clin Cancer Res. 2008 Nov 1;14(21):6886-6894.
Lassiter, L.K.; Tummala, M.K.; Hussain, M.H.; Stadler, W.M.; Petrylak, D.P.; Carducci, M.A. Phase II open-label study of oral piritrexim in patients with advanced carcinoma of the urothelium who have experienced failure with standard chemotherapy. Clin Genitourin Cancer. 2008 Mar;6(1):31-35.
Makarov, D.V.; Humphreys, E.B.; Mangold, L.A.; Carducci, M.A.; Partin, A.W.; Eisenberger, M.A.; Walsh, P.C.; Trock, B.J. The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy. J Urol. 2008 Jan;179(1):156-161; discussion 161-152.
Nelson, J.B.; Love, W.; Chin, J.L.; Saad, F.; Schulman, C.C.; Sleep, D.J.; Qian, J.; Steinberg, J.; Carducci, M. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer. 2008 Nov 1;113(9):2478-2487.
Pili, R., J. Walczak, M. A. Carducci, and S. R. Denmeade. Genitourinary Cancer. In: Donhower, D.E.a.R., editor, Current Cancer in Therapeutics. Philadelphia: Current Medicine Group; 2008.
Rathkopf, D.; Carducci, M.A.; Morris, M.J.; Slovin, S.F.; Eisenberger, M.A.; Pili, R.; Denmeade, S.R.; Kelsen, M.; Curley, T.; Halter, M.; Collins, C.; Fleisher, M.; Heller, G.; Baker, S.D.; Scher, H.I. Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer. J Clin Oncol. 2008 Jun 20;26(18):2959-2965.
Rudin, C.M.; Liu, W.; Desai, A.; Karrison, T.; Jiang, X.; Janisch, L.; Das, S.; Ramirez, J.; Poonkuzhali, B.; Schuetz, E.; Fackenthal, D.L.; Chen, P.; Armstrong, D.K.; Brahmer, J.R.; Fleming, G.F.; Vokes, E.E.; Carducci, M.A.; Ratain, M.J. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol. 2008 Mar 1;26(7):1119-1127.
Scher, H.I.; Halabi, S.; Tannock, I.; Morris, M.; Sternberg, C.N.; Carducci, M.A.; Eisenberger, M.A.; Higano, C.; Bubley, G.J.; Dreicer, R.; Petrylak, D.; Kantoff, P.; Basch, E.; Kelly, W.K.; Figg, W.D.; Small, E.J.; Beer, T.M.; Wilding, G.; Martin, A.; Hussain, M. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008 Mar 1;26(7):1148-1159.
Siu, L.L.; Pili, R.; Duran, I.; Messersmith, W.A.; Chen, E.X.; Sullivan, R.; MacLean, M.; King, S.; Brown, S.; Reid, G.K.; Li, Z.; Kalita, A.M.; Laille, E.J.; Besterman, J.M.; Martell, R.E.; Carducci, M.A. Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. J Clin Oncol. 2008 Apr 20;26(12):1940-1947.
Snyder, C.F.; Garrett-Mayer, E.; Brahmer, J.R.; Carducci, M.A.; Pili, R.; Stearns, V.; Wolff, A.C.; Dy, S.M.; Wu, A.W. Symptoms, supportive care needs, and function in cancer patients: how are they related? Qual Life Res. 2008 Jun;17(5):665-677.
Antonarakis, E.S.; Heath, E.I.; Walczak, J.R.; Nelson, W.G.; Fedor, H.; De Marzo, A.M.; Zahurak, M.L.; Piantadosi, S.; Dannenberg, A.J.; Gurganus, R.T.; Baker, S.D.; Parnes, H.L.; DeWeese, T.L.; Partin, A.W.; Carducci, M.A. Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J Clin Oncol. 2009 Oct 20;27(30):4986-4993.
Baker, S.D.; Verweij, J.; Cusatis, G.A.; van Schaik, R.H.; Marsh, S.; Orwick, S.J.; Franke, R.M.; Hu, S.; Schuetz, E.G.; Lamba, V.; Messersmith, W.A.; Wolff, A.C.; Carducci, M.A.; Sparreboom, A. Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther. 2009 Feb;85(2):155-163.
Diaz, L.A., Jr.; Messersmith, W.; Sokoll, L.; Sinibaldi, V.; Moore, S.; Carducci, M.; Eisenberger, M. TNF-blockade in patients with advanced hormone refractory prostate cancer. Invest New Drugs. 2009 Oct 21.
Kass, N.E.; Sugarman, J.; Medley, A.M.; Fogarty, L.A.; Taylor, H.A.; Daugherty, C.K.; Emerson, M.R.; Goodman, S.N.; Hlubocky, F.J.; Hurwitz, H.I.; Carducci, M.; Goodwin-Landher, A. An intervention to improve cancer patients' understanding of early-phase clinical trials. Irb. 2009 May-Jun;31(3):1-10.
Keizman, D.; Carducci, M.A. Intermittent androgen deprivation-questions remain. Nat Rev Urol. 2009 Aug;6(8):412-414.
Kortenhorst, M.S.; Isharwal, S.; van Diest, P.J.; Chowdhury, W.H.; Marlow, C.; Carducci, M.A.; Rodriguez, R.; Veltri, R.W. Valproic acid causes dose- and time-dependent changes in nuclear structure in prostate cancer cells in vitro and in vivo. Mol Cancer Ther. 2009 Apr;8(4):802-808.
Lin, J.; Carducci, M.A. HIF-1alpha inhibition as a novel mechanism of cardiac glycosides in cancer therapeutics. Expert Opin Investig Drugs. 2009 Feb;18(2):241-243.
Lin, J.; Denmeade, S.; Carducci, M.A. HIF-1alpha and calcium signaling as targets for treatment of prostate cancer by cardiac glycosides. Current cancer drug targets. 2009 Nov;9(7):881-887.
Lin, J.; Gilbert, J.; Rudek, M.A.; Zwiebel, J.A.; Gore, S.; Jiemjit, A.; Zhao, M.; Baker, S.D.; Ambinder, R.F.; Herman, J.G.; Donehower, R.C.; Carducci, M.A. A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors. Clin Cancer Res. 2009 Oct 1;15(19):6241-6249.
Lin, J.; Sinibaldi, V.J.; Carducci, M.A.; Denmeade, S.; Song, D.; Deweese, T.; Eisenberger, M.A. Phase I trial with a combination of docetaxel and (153)Sm-lexidronam in patients with castration-resistant metastatic prostate cancer. Urol Oncol. 2009 Dec 3.
Liu, W.; Laitinen, S.; Khan, S.; Vihinen, M.; Kowalski, J.; Yu, G.; Chen, L.; Ewing, C.M.; Eisenberger, M.A.; Carducci, M.A.; Nelson, W.G.; Yegnasubramanian, S.; Luo, J.; Wang, Y.; Xu, J.; Isaacs, W.B.; Visakorpi, T.; Bova, G.S. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med. 2009 May;15(5):559-565.
Morris, M.J.; Basch, E.M.; Wilding, G.; Hussain, M.; Carducci, M.A.; Higano, C.; Kantoff, P.; Oh, W.K.; Small, E.J.; George, D.; Mathew, P.; Beer, T.M.; Slovin, S.F.; Ryan, C.; Logothetis, C.; Scher, H.I. Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research. Clin Genitourin Cancer. 2009 Jan;7(1):51-57.
Motzer, R.J.; Agarwal, N.; Beard, C.; Bolger, G.B.; Boston, B.; Carducci, M.A.; Choueiri, T.K.; Figlin, R.A.; Fishman, M.; Hancock, S.L.; Hudes, G.R.; Jonasch, E.; Kessinger, A.; Kuzel, T.M.; Lange, P.H.; Levine, E.G.; Margolin, K.A.; Michaelson, M.D.; Olencki, T.; Pili, R.; Redman, B.G.; Robertson, C.N.; Schwartz, L.H.; Sheinfeld, J.; Wang, J. NCCN clinical practice guidelines in oncology: testicular cancer. J Natl Compr Canc Netw. 2009 Jun;7(6):672-693.
Motzer, R.J.; Agarwal, N.; Beard, C.; Bolger, G.B.; Boston, B.; Carducci, M.A.; Choueiri, T.K.; Figlin, R.A.; Fishman, M.; Hancock, S.L.; Hudes, G.R.; Jonasch, E.; Kessinger, A.; Kuzel, T.M.; Lange, P.H.; Levine, E.G.; Margolin, K.A.; Michaelson, M.D.; Olencki, T.; Pili, R.; Redman, B.G.; Robertson, C.N.; Schwartz, L.H.; Sheinfeld, J.; Wang, J. NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw. 2009 Jun;7(6):618-630.
Shabbeer, S.; Sobolewski, M.; Anchoori, R.K.; Kachhap, S.; Davidson, N.; Carducci, M.A.; Khan, S.R. Fenugreek: A naturally occurring edible spice as an anticancer agent. Cancer Biol Ther. 2009 Feb 18;8(3).
Shariat, S.F.; Karam, J.A.; Karakiewicz, P.I. Words of wisdom. Re: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ; Global ARCC Trial. N Engl J Med 2007;356:2271-81. Eur Urol. 2009 Jan;55(1):250-252.
Sharma, P.; Wisniewski, A.; Braga-Basaria, M.; Xu, X.; Yep, M.; Denmeade, S.; Dobs, A.S.; DeWeese, T.; Carducci, M.; Basaria, S. Lack of an effect of high dose isoflavones in men with prostate cancer undergoing androgen deprivation therapy. J Urol. 2009 Nov;182(5):2265-2272.
Snyder, C.F.; Garrett-Mayer, E.; Blackford, A.L.; Brahmer, J.R.; Carducci, M.A.; Pili, R.; Stearns, V.; Wolff, A.C.; Dy, S.M.; Wu, A.W. Concordance of cancer patients' function, symptoms, and supportive care needs. Qual Life Res. 2009 Oct;18(8):991-998.
Antonarakis, E.S.; Carducci, M.A. Future directions in castrate-resistant prostate cancer therapy. Clin Genitourin Cancer. 2010 Dec 1;8(1):37-46.
Antonarakis, E.S.; Carducci, M.A. Combining low-dose cyclophosphamide with GM-CSF-secreting prostate cancer immunotherapy enhances antitumor immune effects. Expert Opin Investig Drugs. 2010 Feb;19(2):311-314.
Antonarakis, E.S.; Carducci, M.A.; Eisenberger, M.A. Novel targeted therapeutics for metastatic castration-resistant prostate cancer. Cancer Lett. 2010 May 1;291(1):1-13.
Armstrong, A.J.; Netto, G.J.; Rudek, M.A.; Halabi, S.; Wood, D.P.; Creel, P.A.; Mundy, K.; Davis, S.L.; Wang, T.; Albadine, R.; Schultz, L.; Partin, A.W.; Jimeno, A.; Fedor, H.; Febbo, P.G.; George, D.J.; Gurganus, R.; De Marzo, A.M.; Carducci, M.A. A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer. Clin Cancer Res. 2010 Jun 1;16(11):3057-3066.
Cetin, K.; Beebe-Dimmer, J.L.; Fryzek, J.P.; Markus, R.; Carducci, M.A. Recent time trends in the epidemiology of stage IV prostate cancer in the United States: analysis of data from the Surveillance, Epidemiology, and End Results Program. Urology. 2010 Jun;75(6):1396-1404.
DiPaola, R.S.; Chen, Y.H.; Stein, M.; Vaughn, D.; Patrick-Miller, L.; Carducci, M.; Roth, B.; White, E.; Wilding, G. A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899. J Transl Med. 2010;8:20.
Franke, R.M.; Carducci, M.A.; Rudek, M.A.; Baker, S.D.; Sparreboom, A. Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. J Clin Oncol. 2010 Oct 20;28(30):4562-4567.
Kachhap, S.K.; Rosmus, N.; Collis, S.J.; Kortenhorst, M.S.; Wissing, M.D.; Hedayati, M.; Shabbeer, S.; Mendonca, J.; Deangelis, J.; Marchionni, L.; Lin, J.; Hoti, N.; Nortier, J.W.; DeWeese, T.L.; Hammers, H.; Carducci, M.A. Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor. PLoS One. 2010;5(6):e11208.
Research Interests
- Development and Evaluation of New Therapies for Urologic Cancers
More Info
Languages
- English
Memberships
Journal Citations continued:
Snyder, C.F.; Blackford, A.L.; Brahmer, J.R.; Carducci, M.A.; Pili, R.; Stearns, V.; Wolff, A.C.; Dy, S.M.; Wu, A.W. Needs assessments can identify scores on HRQOL questionnaires that represent problems for patients: an illustration with the Supportive Care Needs Survey and the QLQ-C30. Qual Life Res. 2010 Aug;19(6):837-845.
Snyder, C.F.; Frick, K.D.; Blackford, A.L.; Herbert, R.J.; Neville, B.A.; Carducci, M.A.; Earle, C.C. How does initial treatment choice affect short-term and long-term costs for clinically localized prostate cancer? Cancer. 2010 Dec 1;116(23):5391-5399.
Snyder, C.F.; Jensen, R.E.; Geller, G.; Carducci, M.A.; Wu, A.W. Relevant content for a patient-reported outcomes questionnaire for use in oncology clinical practice: Putting doctors and patients on the same page. Qual Life Res. 2010 Sep;19(7):1045-1055.
Snyder, C.F.; Stein, K.B.; Barone, B.B.; Peairs, K.S.; Yeh, H.C.; Derr, R.L.; Wolff, A.C.; Carducci, M.A.; Brancati, F.L. Does pre-existing diabetes affect prostate cancer prognosis? A systematic review. Prostate Cancer Prostatic Dis. 2010 Mar;13(1):58-64.
Lin, J.; Haffner, M.C.; Zhang, Y.; Lee, B.H.; Brennen, W.N.; Britton, J.; Kachhap, S.K.; Shim, J.S.; Liu, J.O.; Nelson, W.G.; Yegnasubramanian, S.; Carducci, M.A. Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth. Prostate. 2011 Mar 1;71(4):333-343.
Napora, J.K.; Short, R.G.; Muller, D.C.; Carlson, O.D.; Odetunde, J.O.; Xu, X.; Carducci, M.; Travison, T.G.; Maggio, M.; Egan, J.M.; Basaria, S. High-dose isoflavones do not improve metabolic and inflammatory parameters in androgen-deprived men with prostate cancer. J Androl. 2011 Jan-Feb;32(1):40-48.
Snyder, C.F.; Blackford, A.L.; Brahmer, J.R.; Carducci, M.A.; Pili, R.; Stearns, V.; Wolff, A.C.; Dy, S.M.; Wu, A.W. Needs assessments can identify scores on HRQOL questionnaires that represent problems for patients: an illustration with the Supportive Care Needs Survey and the QLQ-C30. Qual Life Res. 2010 Aug;19(6):837-845.
Snyder, C.F.; Frick, K.D.; Blackford, A.L.; Herbert, R.J.; Neville, B.A.; Carducci, M.A.; Earle, C.C. How does initial treatment choice affect short-term and long-term costs for clinically localized prostate cancer? Cancer. 2010 Dec 1;116(23):5391-5399.
Snyder, C.F.; Jensen, R.E.; Geller, G.; Carducci, M.A.; Wu, A.W. Relevant content for a patient-reported outcomes questionnaire for use in oncology clinical practice: Putting doctors and patients on the same page. Qual Life Res. 2010 Sep;19(7):1045-1055.
Snyder, C.F.; Stein, K.B.; Barone, B.B.; Peairs, K.S.; Yeh, H.C.; Derr, R.L.; Wolff, A.C.; Carducci, M.A.; Brancati, F.L. Does pre-existing diabetes affect prostate cancer prognosis? A systematic review. Prostate Cancer Prostatic Dis. 2010 Mar;13(1):58-64.
Lin, J.; Haffner, M.C.; Zhang, Y.; Lee, B.H.; Brennen, W.N.; Britton, J.; Kachhap, S.K.; Shim, J.S.; Liu, J.O.; Nelson, W.G.; Yegnasubramanian, S.; Carducci, M.A. Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth. Prostate. 2011 Mar 1;71(4):333-343.
Napora, J.K.; Short, R.G.; Muller, D.C.; Carlson, O.D.; Odetunde, J.O.; Xu, X.; Carducci, M.; Travison, T.G.; Maggio, M.; Egan, J.M.; Basaria, S. High-dose isoflavones do not improve metabolic and inflammatory parameters in androgen-deprived men with prostate cancer. J Androl. 2011 Jan-Feb;32(1):40-48.
Clinical Trials
- Phase I
- Prostate Cancer
- Kidney Cancer
Additional Resources
Facebook
Twitter
Sharecare
Blogs
YouTube
RSS
Podcasts